US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Courts Rule On DOJ Trans Care Subpoena, Abortion And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at a split Ninth Circuit decision backing the U.S. Department of Justice's administrative subpoena o... (more story)

Iowa Board Opens Door For Doctor Self-Defense Arguments No Photo Available

Mark Payne

An Iowa medical board's decision to dismiss disciplinary charges against a doctor who claimed the state's "stand your ground" law enab... (more story)

Lilly's Obesity Drug Suits Signal New Reality For GLP-1 Giants No Photo Available

Yeji Jesse Lee

Obesity-drug makers haven’t been shy about suing players encroaching on their turf. But a new round of lawsuits from Eli Lilly may sig... (more story)